Use of amiloride and multiple sclerosis: Registry-based cohort studies
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Use of amiloride and multiple sclerosis : Registry-based cohort studies. / Pasternak, Björn; Svanström, Henrik; Nielsen, Nete M.; Melbye, Mads; Hviid, Anders.
In: Pharmacoepidemiology and Drug Safety, Vol. 21, No. 8, 08.2012, p. 890-895.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Use of amiloride and multiple sclerosis
T2 - Registry-based cohort studies
AU - Pasternak, Björn
AU - Svanström, Henrik
AU - Nielsen, Nete M.
AU - Melbye, Mads
AU - Hviid, Anders
PY - 2012/8
Y1 - 2012/8
N2 - Purpose: Amiloride reduces functional neurological deficits and neuronal damage in animal models of multiple sclerosis (MS). We investigated whether amiloride use was associated with reduced risk of incident MS and of MS hospitalization and death in humans. Methods: We conducted two propensity score-matched cohort studies, linking nationwide registry data on filled drug prescriptions, diagnostic information, and covariates. First, we compared rates of incident MS in new users of amiloride and new users of an active control treatment, thiazide diuretics. Second, rates of hospitalizations for MS and of death were compared between users of amiloride and thiazides in a cohort of MS patients. Treatment groups were matched 1:4 on propensity scores that included a wide range of covariates, and Cox regression was used to estimate hazard ratios (HRs). Results: Comparing 36659 users of amiloride and 177031 users of thiazides, there were 19 cases of incident MS during 92548 person-years of follow-up among amiloride users and 81 cases during 567599 person-years of follow-up among thiazide users. There was no significantly decreased risk of MS associated with amiloride use (HR 1.34, 95%CI 0.81-2.20). In the cohort of MS patients, amiloride use was not associated with significantly decreased risk of MS hospitalization (HR 1.11, 95%CI 0.79-1.59) or death (HR 1.38, 95%CI 0.83-2.28). Conclusion: Amiloride use was not associated with significantly decreased risk of incident MS or hospitalizations and death among patients with MS. Because amiloride users were represented by older patients, risks could not be evaluated in younger individuals.
AB - Purpose: Amiloride reduces functional neurological deficits and neuronal damage in animal models of multiple sclerosis (MS). We investigated whether amiloride use was associated with reduced risk of incident MS and of MS hospitalization and death in humans. Methods: We conducted two propensity score-matched cohort studies, linking nationwide registry data on filled drug prescriptions, diagnostic information, and covariates. First, we compared rates of incident MS in new users of amiloride and new users of an active control treatment, thiazide diuretics. Second, rates of hospitalizations for MS and of death were compared between users of amiloride and thiazides in a cohort of MS patients. Treatment groups were matched 1:4 on propensity scores that included a wide range of covariates, and Cox regression was used to estimate hazard ratios (HRs). Results: Comparing 36659 users of amiloride and 177031 users of thiazides, there were 19 cases of incident MS during 92548 person-years of follow-up among amiloride users and 81 cases during 567599 person-years of follow-up among thiazide users. There was no significantly decreased risk of MS associated with amiloride use (HR 1.34, 95%CI 0.81-2.20). In the cohort of MS patients, amiloride use was not associated with significantly decreased risk of MS hospitalization (HR 1.11, 95%CI 0.79-1.59) or death (HR 1.38, 95%CI 0.83-2.28). Conclusion: Amiloride use was not associated with significantly decreased risk of incident MS or hospitalizations and death among patients with MS. Because amiloride users were represented by older patients, risks could not be evaluated in younger individuals.
KW - Amiloride
KW - Cohort studies
KW - Multiple sclerosis
KW - Neuron degeneration
KW - Registries
UR - http://www.scopus.com/inward/record.url?scp=85027929568&partnerID=8YFLogxK
U2 - 10.1002/pds.3269
DO - 10.1002/pds.3269
M3 - Journal article
C2 - 22555991
AN - SCOPUS:85027929568
VL - 21
SP - 890
EP - 895
JO - Pharmacoepidemiology and Drug Safety
JF - Pharmacoepidemiology and Drug Safety
SN - 1053-8569
IS - 8
ER -
ID: 258839025